RemeGen Co. Ltd. A

Price Chart

Risk-Adjusted Performance

RemeGen Co. Ltd. A (688331) Price Performance

RemeGen Co. Ltd. A (688331) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY116.45, down 0.24% from the previous close.

Over the past year, 688331 has traded between a low of CNY35.84 and a high of CNY118.90. The stock has gained 224.9% over this period. It is currently 224.9% above its 52-week low.

RemeGen Co. Ltd. A has a market capitalization of $69.48B.

About RemeGen Co. Ltd. A

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.